The 2021 European Heart Failure Guidelines: The Case for Personalised Therapeutics.

Abstract

© RADCLIFFE CARDIOLOGY 2022 www.ECRjournal.com The field of heart failure (HF) has seen the development of unparalleled evidence-based therapies over the last 30 years, with continuous improvement in survival and quality of life for our patients. It is unquestionably an exciting time to be considering or pursuing HF as a subspecialty. Pivotal to and underpinning these advances is the guidance provided by international HF guidelines, particularly from the European Society of Cardiology (ESC). The new 2021 ESC HF guidelines have a total of 41 new and 15 modified recommendations from the 2016 document.1